Anzeige
Erschienen in:
01.03.2015 | Original Article – Clinical Oncology
The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy
Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2015
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Although androgen-deprivation therapy (ADT) for prostate cancer is initially effective, most tumors eventually recur even during ADT. To predict their prognosis, the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score was developed. However, there is no validation of this model using data from a single institution. Therefore, in this study, we clarified the oncological outcome of primary ADT and its prognostic factors, as well as validated the J-CAPRA score model in our institution.
Methods
This study included 248 Japanese patients with hormone-naïve prostate cancer who were treated with primary ADT from 1996 through 2012. The oncological outcome and prognostic significance of several clinicopathological factors were analyzed. Also, J-CAPRA risk stratification model was validated in this cohort.
Results
During a median follow-up period of 42.2 months, the median progression-free survival (PFS) and overall survival (OS) were 89.3 and 103.3 months, respectively. Multivariate analysis identified clinical T-stage and M-stage for PFS and cancer-specific survival (CSS) and clinical M-stage for OS as significant predictors. The accuracy of J-CAPRA score model for predicting PFS, CSS, and OS was validated by high c-indices.
Conclusions
This study demonstrated the use of the J-CAPRA score system for predicting PFS, CSS, and OS among Japanese men treated with primary ADT in a single institution.